New Review Suggests PSA Screening May Lower Prostate Cancer Mortality Rates
A recent review indicates that prostate-specific antigen (PSA) blood testing may significantly reduce deaths associated with prostate cancer.
Editorial Staff
1 min read
Updated 7 days ago
A new review has found that prostate-specific antigen (PSA) blood testing is likely to lower the risk of mortality from prostate cancer.
This finding suggests that regular screening could be an important tool in managing prostate cancer outcomes.
As the medical community continues to evaluate screening practices, this review adds to the ongoing discussion about the benefits of PSA testing.